Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03740126

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

The purpose of this study is to improve early detection of treatable relapse of lung cancer and thereby improve survival and quality of life for the patients. The investigators will perform a multicenter, randomized controlled trial to 1) assess if surveillance with whole body Positron Emission Tomography combined with Computer Tomography (PET/CT) including the brain can increase the number of treatable relapses and 2) concurrently collect liquid biopsies for later analysis, potentially enabling even earlier and minimally invasive detection and characterization of relapse.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Carcinoma, Non-Small-Cell Lung Bronchial Neoplasms Carcinoma, Bronchogenic Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rigshospitalet, Copenhagen, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with non-small cell lung cancer (NSCLC), proven by cytology or histology
  • Patient in clinical stages I-III
  • Age≥ 18 years
  • Performance status ≤ 2 at the time of referral to therapy
  • Patient referred for definitive treatment (e.g. surgery, surgery followed by adjuvant chemotherapy, concomitant radio-chemotherapy, conventional or stereotactic radiotherapy or radiofrequency ablation).
  • Patient has given his/her written informed consent before any specific procedure from protocol

Exclusion criteria

  • Patient, whose disease has progressed within the first 3 months after cancer treatment, e.g. confirmed progressive disease on CT.
  • Persons deprived of liberty or under guardianship or curators
  • Dementia, mental alteration, severe psychiatric disease or other circumstances that can compromise informed consent from the patient and/or adherence to the protocol and the monitoring of the trial
  • Pregnant or breastfeeding women
  • Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention, whereas studies on late effects will not preclude participation in SUPE-R. Participation in protocols related only to initial treatment will not preclude participation in SUPE-R. Cases of doubt will be settled by the steering committee.

Treatment and study plan

Whole body 18F-FDG PET/CT

Diagnostic Test

In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.

Primary outcomes

  1. Number of relapses treatable with curative intent

    Time frame: Until first detected relapse or 2 years after enrollment

    As decided by multidisciplinary meetings

Secondary outcomes

  1. Time to verified relapse

    Time frame: From date of randomization until the date of first documented relapse assessed up to 24 months

    Relapse verified by histology or imaging combined with MDM review

  2. Overall survival

    Time frame: From date of randomization until the date of censoring or death from any cause, whichever came first, assessed up to 36 months

    Death of any course or censoring

  3. Overall survival for patients with relapse

    Time frame: From randomization until 12 months after first detected relapse or until death (whichever comes first)

    Death of any course or censoring

  4. Performance status at relapse

    Time frame: From randomization until first detected relapse or 24 months

    Performance status of study participants at relapse will be assessed using Eastern Cooperative Oncology Group (ECOG) performance status scale from grade 0 to grade 4, where grade 0 corresponds to a patient who is "fully active, able to carry on all pre-disease performance without restriction" and grade 4 is a patient who is "completely disabled; cannot carry on any selfcare; totally confined to bed or chair".

  5. Quality of life / QLQ-C30

    Time frame: From randomization until first detected relapse or 24 months

    Quality of life will be assessed every 3rd month using a validated questionnaire, European Organisation for Research and Treatment of Cancer Quality of Life Questionaire Core Questionaire 30 (EORTC QLQ-C30).

    The questionaire is filled out by study participants at each control visit and patients score severity of a range of symptoms during the past week on a scale of 1 ("Not at all") to 4 ("Very much").

  6. Quality of life / QLQ-LC13

    Time frame: From randomization until first detected relapse or 24 months

    Quality of life will be assessed every 3rd month using a validated questionnaire, European Organisation for Research and Treatment of Cancer Quality of Life Questionair Lung Cancer 13 (EORTC QLQ-LC13).

    The questionaire is filled out by study participants at each control visit and patients score severity of a range of symptoms during the past week on a scale of 1 ("Not at all") to 4 ("Very much").

  7. Quality of life / Raw score

    Time frame: From randomization until first detected relapse or 24 months

    From the results of QLQ-C30 and QLQ-LC13 a Raw Score (RS) is calculated (average of all scores) and Quality of Life is calculated as (RS - 1)/3 which outputs a value between 0 and 1, where 0 is a complete absence of symptoms and 1 is the maximum severity of all related symptoms. This will be used for calculation of QALY in the cost-effectiveness analysis.

  8. Number of procedures to assess incidental findings

    Time frame: From randomization until 24 months or first detected relapse or until death (whichever comes first)

    Procedures resulting from an incidental finding on a follow up scan

  9. Types of procedures to assess incidental findings

    Time frame: From randomization until 24 months or first detected relapse or until death (whichever comes first)

    Invasive / non-invasive

  10. Adverse events due to invasive procedures done to assess incidental findings

    Time frame: From randomization until 24 months or first detected relapse or until death (whichever comes first)

    For example: Bleeding, pneumothorax, hospital admission

  11. Cost-effectiveness analysis of intervention

    Time frame: From randomization until 24 months or 12 months after first detected relapse or until death (whichever comes first)

    Cost-effectiveness of the PET/CT regimen vs the CT regimen is assessed with the ICER (incremental cost-effectiveness ratio), i.e. the ratio of net health care costs to net QALYs ( quality-adjusted life years). Net health care costs are estimated as the health care costs difference between the two arms and net QALYs likewise. Health care costs are calculated from register-based information on health care consumption cumulated in 2-yrs follow-up (DRG-rates) supplemented by intervention costs based on project costs. The relevant cost data are available at "Sundhedsdatastyrelsen" using their research service.

  12. Type of treatment after verification of relapse

    Time frame: From randomization until 12 months after first detected relapse or until death (whichever comes first)

    Description of treatment - e.g. surgical, radiotherapy, stereotactic ablative body radiotherapy, medical treatment

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • Danish Comprehensive Cancer Center
  • Danish Lung Cancer Group

Registry information

Official study title

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy; a Randomized Controlled Trial

Acronym: SUPE_R

Important dates

Study start
2018
Primary completion
2023
Study completion
2026
First posted
Nov 14, 2018
Registry last updated
Aug 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.